FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954304003> ?p ?o ?g. }

• W2954304003 abstract "2527 Background: The prognosis of patients with advanced non small cell lung cancer (NSCLC) remains dismal. Epidermal Growth Factor Receptor (EGFR) is overexpressed in epithelial tumors and its role in the development of NSCLC is widely proven. The EGF vaccine is a therapeutic cancer vaccine composed by recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides and Montanide, as adjuvant. The vaccine is intended to induce antibodies against self EGF that would block EGF-EGFR interaction. Methods: A multicentric, randomized Phase III trial was designed to assess the efficacy, immunogenicity and safety of the EGF cancer vaccine in advanced NSCLC patients. Patients older than 18 years with histology or cytology proven NSCLC at stage IIIB and IV were enrolled in the trial. All patients received no less than 4 platinum-based cycles and achieved at least stable disease, before entering the trial. A low-dose of cyclophosphamide was administered 3 days before the first immunization. Then, patients received 4 quarterly immunizations followed by monthly re-immunizations. Control patients received best supportive care. Results: In total, 405 patients bearing stage IIIB/IV NSCLC were recruited in 21 sites. The vaccine was very well tolerated. The most frequent adverse events consisted in grade 1/2 injection site pain, fever, headache, vomiting and chills. The vaccine was immunogenic. Antibody titers against EGF significantly increased with vaccination and on the contrary, EGF concentration in sera showed a fast reduction after immunization. There was an inverse correlation between the anti-EGF antibody titers and the EGF concentration in sera. Baseline EGF concentration was a worse prognostic factor for the control patients and a predictive factor for vaccinated subjects. The overall survival was significantly better for vaccinated patients as compared to controls. There was a direct correlation between the antibody titers and survival. Conclusions: The EGF cancer vaccine was very well tolerated and significantly increased overall survival of the vaccinated patients. Baseline EGF concentration predicted survival benefit. The EGF vaccine is a new therapeutic option for advanced NSCLC patients." @default.
• W2954304003 created "2019-07-12" @default.
• W2954304003 creator A5006318317 @default.
• W2954304003 creator A5010072218 @default.
• W2954304003 creator A5011498992 @default.
• W2954304003 creator A5011619590 @default.
• W2954304003 creator A5026932532 @default.
• W2954304003 creator A5035594109 @default.
• W2954304003 creator A5042491150 @default.
• W2954304003 creator A5067739096 @default.
• W2954304003 creator A5070534105 @default.
• W2954304003 creator A5076253948 @default.
• W2954304003 creator A5079606668 @default.
• W2954304003 creator A5082455874 @default.
• W2954304003 creator A5091661570 @default.
• W2954304003 date "2012-05-20" @default.
• W2954304003 modified "2023-09-22" @default.
• W2954304003 title "EGF-based cancer vaccine for advanced NSCLC: Results from a phase III trial." @default.
• W2954304003 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.2527" @default.
• W2954304003 hasPublicationYear "2012" @default.
• W2954304003 type Work @default.
• W2954304003 sameAs 2954304003 @default.
• W2954304003 citedByCount "1" @default.
• W2954304003 countsByYear W29543040032016 @default.
• W2954304003 crossrefType "journal-article" @default.
• W2954304003 hasAuthorship W2954304003A5006318317 @default.
• W2954304003 hasAuthorship W2954304003A5010072218 @default.
• W2954304003 hasAuthorship W2954304003A5011498992 @default.
• W2954304003 hasAuthorship W2954304003A5011619590 @default.
• W2954304003 hasAuthorship W2954304003A5026932532 @default.
• W2954304003 hasAuthorship W2954304003A5035594109 @default.
• W2954304003 hasAuthorship W2954304003A5042491150 @default.
• W2954304003 hasAuthorship W2954304003A5067739096 @default.
• W2954304003 hasAuthorship W2954304003A5070534105 @default.
• W2954304003 hasAuthorship W2954304003A5076253948 @default.
• W2954304003 hasAuthorship W2954304003A5079606668 @default.
• W2954304003 hasAuthorship W2954304003A5082455874 @default.
• W2954304003 hasAuthorship W2954304003A5091661570 @default.
• W2954304003 hasConcept C121608353 @default.
• W2954304003 hasConcept C126322002 @default.
• W2954304003 hasConcept C143998085 @default.
• W2954304003 hasConcept C2777701055 @default.
• W2954304003 hasConcept C2778378633 @default.
• W2954304003 hasConcept C535046627 @default.
• W2954304003 hasConcept C71924100 @default.
• W2954304003 hasConceptScore W2954304003C121608353 @default.
• W2954304003 hasConceptScore W2954304003C126322002 @default.
• W2954304003 hasConceptScore W2954304003C143998085 @default.
• W2954304003 hasConceptScore W2954304003C2777701055 @default.
• W2954304003 hasConceptScore W2954304003C2778378633 @default.
• W2954304003 hasConceptScore W2954304003C535046627 @default.
• W2954304003 hasConceptScore W2954304003C71924100 @default.
• W2954304003 hasLocation W29543040031 @default.
• W2954304003 hasOpenAccess W2954304003 @default.
• W2954304003 hasPrimaryLocation W29543040031 @default.
• W2954304003 hasRelatedWork W1864531900 @default.
• W2954304003 hasRelatedWork W1994094811 @default.
• W2954304003 hasRelatedWork W2026836017 @default.
• W2954304003 hasRelatedWork W2050579390 @default.
• W2954304003 hasRelatedWork W2113451729 @default.
• W2954304003 hasRelatedWork W2149282317 @default.
• W2954304003 hasRelatedWork W2381700526 @default.
• W2954304003 hasRelatedWork W2563308044 @default.
• W2954304003 hasRelatedWork W2565551586 @default.
• W2954304003 hasRelatedWork W2600998681 @default.
• W2954304003 hasRelatedWork W2737585839 @default.
• W2954304003 hasRelatedWork W2799500124 @default.
• W2954304003 hasRelatedWork W2901105904 @default.
• W2954304003 hasRelatedWork W2937778354 @default.
• W2954304003 hasRelatedWork W2942201468 @default.
• W2954304003 hasRelatedWork W2966111302 @default.
• W2954304003 hasRelatedWork W2988192292 @default.
• W2954304003 hasRelatedWork W3031187831 @default.
• W2954304003 hasRelatedWork W3031562346 @default.
• W2954304003 hasRelatedWork W3161736209 @default.
• W2954304003 isParatext "false" @default.
• W2954304003 isRetracted "false" @default.
• W2954304003 magId "2954304003" @default.
• W2954304003 workType "article" @default.